Navigation Links
EVICEL(TM) Fibrin Sealant (Human) Approved for General Hemostasis in Surgery
Date:1/10/2008

Indication positions EVICEL(TM) as the only aprotinin-free fibrin sealant

option for a broad range of surgical procedures.

SOMERVILLE, N.J., Jan. 10 /PRNewswire/ -- ETHICON, INC. announced today that the U.S. Food and Drug Administration has granted an expanded indication for EVICEL(TM) Fibrin Sealant (Human). The product is the first fibrin sealant to be indicated as an adjunct to hemostasis for use in patients undergoing surgery, when control of bleeding by standard surgical techniques is ineffective or impractical.

EVICEL(TM) is the only all-human plasma-derived fibrin sealant commercially available in the U.S. It does not contain aprotinin, which has been associated with adverse health effects. EVICEL(TM) is easy to use and readily available for time-sensitive needs in the operating room. The product is sold as a frozen liquid and requires less than one minute preparation time after thawing.

"In surgery, the success of the procedure can sometimes depend upon the surgeon's ability to control blood loss quickly and effectively," said R. Clement Darling III, M.D., head of the Division of Vascular Surgery at Albany Medical Center. "EVICEL(TM) has become an important element of hemostasis in many liver and vascular procedures. The expansion of its indication to general surgery will bring the benefits of this product to more surgeons and their patients," added Dr. Darling.

EVICEL(TM) is contraindicated in individuals known to have anaphylactic or severe systemic reaction to human blood products. As with all plasma-derived products, the risk of transmitting infectious agents cannot be completely eliminated. EVICEL(TM) should not be injected directly into the circulatory system or used for the treatment of severe or brisk arterial bleeding. Anaphylactic reactions may occur. No adverse events of this type were reported during the conduction of the clinical trials.

EVICEL(TM) was developed by ETHICON, INC. in collaboration with OMRIX Biopharmaceuticals.

About ETHICON, INC.

ETHICON, INC., a Johnson & Johnson company, is a global medical device company that develops and markets surgical products for use in general surgery, wound management and women's health & urology. Johnson & Johnson Wound Management, a division of ETHICON, INC., offers a complete portfolio of topical and advanced hemostatic products including SURGICEL(R) Absorbable Hemostats, SURGIFOAM* Absorbable Gelatin Sponge, EVICEL(TM) Fibrin Sealant (Human), and SURGIFLO* Hemostatic Matrix with FlexTip. For more information about ETHICON, INC., please visit http://www.ethicon.com.

* Trademark


'/>"/>
SOURCE ETHICON, INC.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
2. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
3. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
4. Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
5. Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer
6. Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") Notices Posted to Shareholders
7. Sinovac Announces Postponement of Annual General Meeting
8. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
9. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
10. CryoLife Names Philip Theodore as Vice President, General Counsel
11. 3SBio Inc. to Hold Annual General Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... The Fight Against Cancer Innovation Trust (FACIT) and the ... report that Fusion Pharmaceuticals Inc. (Fusion) has closed a ... – JJDC, Inc. (JJDC) as the lead investor. Additional, ... and Genesys Capital, as well as founding investor FACIT.  ... ...
(Date:2/23/2017)... , Feb. 23, 2017  In Atlanta, it seems ... fashion, and culture intertwine to create an expressive and dynamic ... reflect this energy and contribute to it. ... Hair Fairies seeks to carry on that tradition ... Atlanta salon is the newest of ...
(Date:2/23/2017)... , Feb. 23, 2017  Imanis Life ... product line of oncolytic vaccinia viruses for virotherapy ... as part of Genelux,s proprietary, vaccinia virus-based technology ... excited to enter into a partnership with Genelux ... oncolytic vaccinia viruses for use in research," said ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... of multiple immunoassay-based threat detection technologies by researchers from the Pacific National ... threat detection technology was found to have the best level of detection ...
Breaking Biology Technology:
(Date:2/7/2017)... 7, 2017   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... innovative, highly flexible and award winning eClinical solution, is ... iMedNet is a proven Software-as-a-Service (SaaS) clinical research ... (EDC), but also delivers an entire suite of eClinical ...
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute ... Larry Schlesinger as the Institute,s new President ... Biomed effective May 31, 2017. He is currently the Chair ... of the Center for Microbial Interface Biology at Ohio State ... as the new President and CEO of Texas Biomed," said ...
(Date:2/2/2017)... 2017  Central to its deep commitment to ... The Japan Prize Foundation today announced the laureates ... the envelope in their respective fields of Life ... are being recognized with the 2017 Japan Prize ... contribute to the advancement of science and technology, ...
Breaking Biology News(10 mins):